1. Home /
  2. Drug Approvals

Drug Approvals

Deciphera Soars on Positive Phase III Drug Trial

Deciphera Soars on Positive Phase III Drug Trial

Deciphera Pharma stock more than doubled on positive results from a Phase III clinical study of its drug to treat patients with advanced gastrointestinal stromal tumors.

Checking In on 2 Small Biotech Names That Had Big Quarters

Checking In on 2 Small Biotech Names That Had Big Quarters

Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.

Amarin Dives on Surprise FDA Heart-Drug Review

Amarin Dives on Surprise FDA Heart-Drug Review

Shares of Amarin plunge after the biotech company's surprise revelation that the Food and Drug Administration will hold an advisory panel review of its heart drug Vascepa.

Canopy Growth to Buy Beckley Canopy Therapeutics

Canopy Growth to Buy Beckley Canopy Therapeutics

Canopy Growth agrees to buy Beckley Canopy Therapeutics, a joint venture it initially launched in 2018 to research and develop cannabis-based medicines.

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.

2 Promising $5 Biotech Stocks to Consider on Recent News

2 Promising $5 Biotech Stocks to Consider on Recent News

Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Pfizer, Mylan Plan to Combine Generic Drug Business: Reports

Pfizer, Mylan Plan to Combine Generic Drug Business: Reports

Shareholders of Mylan would get around 40% of the newly formed business and Pfizer shareholders would get the remaining 60%, according to Reuters.

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?